Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34<sup>+</sup> cells to imatinib by Hatziieremia, S. et al.
 
 
 
 
 
 
 
Hatziieremia, S., Jordanides, N.E., Holyoake, T.L., Mountford, 
J.C. and Jorgensen, H.G. (2009) Inhibition of MDR1 does not sensitize 
primitive chronic myeloid leukemia CD34+ cells to 
imatinib. Experimental Hematology, 37 (6). pp. 692-700. ISSN 0301-
472X 
 
http://eprints.gla.ac.uk/18524/ 
 
Deposited on: 24 November 2011 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
                             Editorial Manager(tm) for Experimental Hematology
                                  Manuscript Draft
Manuscript Number: 
Title: Inhibition of MDR1 does not sensitise primitive chronic myeloid leukaemia CD34+ cells to 
imatinib
Article Type: Regular Submission
Keywords: BCR-ABL; chronic myeloid leukaemia; imatinib mesylate; ATP-binding cassette (ABC) efflux 
transporters; MDR1.
Corresponding Author: Dr Heather Graham Jorgensen, PhD
Corresponding Author's Institution: University of Glasgow
First Author: Sophia Hatziieremia, BSc, PhD
Order of Authors: Sophia Hatziieremia, BSc, PhD; Niove  E Jordanides, BSc, PhD; Tessa L Holyaoke, MD, 
PhD; Joanne  C Mountford, BSc, PhD; Heather Graham Jorgensen, PhD
Abstract: Objective
To investigate the interaction of imatinib mesylate (IM) with the clinically relevant ATP-binding 
cassette (ABC) efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukaemia 
(CML), to explore whether inhibition of this transporter would improve IM's efficacy in the elimination 
of CML CD34+ cells by increasing cell associated drug accumulation.
Methods
Cells from newly diagnosed chronic phase CML patients were harvested by leukapheresis and enriched 
to >95% CD34+. Expression of the transporter gene MDR1 was performed by qRT-PCR. Interaction of 
IM with MDR1 was analysed by substrate (rhodamine 123) displacement assay. Cell associated levels 
of IM in CML CD34+ cells were measured by HPLC. Intracellular phospho-CrkL (p-CrkL) levels, 
apoptosis in total CML CD34+ cells and high resolution tracking of cell division were assayed by flow 
cytometry. 
Results
Measurements of cell associated IM uptake showed significantly lower drug levels in CD34+ cells, 
particularly the CD38- sub-population, as compared to IM sensitive K562 cells. MDR1 was expressed at 
low level and dye efflux studies demonstrated very little MDR1 activity in CML CD34+ cells. 
Furthermore, combination treatment of primitive CML cells, with IM and the MDR1 inhibitor PSC833, 
did not result in elevated cell associated IM levels. Although we observed slightly enhanced cytostasis 
with IM when combined with PSC833, this was independent of BCR-ABL inhibition as no associated 
decrease in p-CrkL was observed. 
Conclusions
Our findings demonstrate that inhibition of MDR1 neither enhances the effect of IM against BCR-ABL 
activity, nor significantly potentiates IM's efficiency in eliminating primitive CML cells. 
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2Objective
To investigate the interaction of imatinib mesylate (IM) with the clinically relevant 
ATP-binding cassette (ABC) efflux transporter MDR1 (ABCB1) in cells from 
patients with chronic myeloid leukaemia (CML), to explore whether inhibition of this
transporter would improve IM’s efficacy in the elimination of CML CD34+ cells by 
increasing cell associated drug accumulation.
Methods
Cells from newly diagnosed chronic phase CML patients were harvested by 
leukapheresis and enriched to >95% CD34+. Expression of the transporter gene 
MDR1 was performed by qRT-PCR. Interaction of IM with MDR1 was analysed by 
substrate (rhodamine 123) displacement assay. Cell associated levels of IM in CML 
CD34+ cells were measured by HPLC. Intracellular phospho-CrkL (p-CrkL) levels, 
apoptosis in total CML CD34+ cells and high resolution tracking of cell division were 
assayed by flow cytometry. 
Results
Measurements of cell associated IM uptake showed significantly lower drug levels in 
CD34+ cells, particularly the CD38- sub-population, as compared to IM sensitive 
K562 cells. MDR1 was expressed at low level and dye efflux studies demonstrated 
very little MDR1 activity in CML CD34+ cells. Furthermore, combination treatment 
of primitive CML cells, with IM and the MDR1 inhibitor PSC833, did not result in 
elevated cell associated IM levels. Although we observed slightly enhanced cytostasis
with IM when combined with PSC833, this was independent of BCR-ABL inhibition 
as no associated decrease in p-CrkL was observed. 
Conclusions
Our findings demonstrate that inhibition of MDR1 neither enhances the effect of IM 
against BCR-ABL activity, nor significantly potentiates IM’s efficiency in eliminating 
primitive CML cells. 
Keywords:  BCR-ABL; chronic myeloid leukaemia (CML); imatinib mesylate (IM); 
ATP-binding cassette (ABC) efflux transporters; MDR1.
3Introduction
Imatinib mesylate (IM; Glivec/Gleevec, Novartis Pharma AG, Basel, Switzerland) 
is a drug targeted against the Philadelphia (Ph) chromosome product,  BCR-ABL 
tyrosine kinase, that has proven to be remarkably effective in the treatment of patients 
with chronic myeloid leukaemia (CML) in early chronic phase (CP).[1] However, 
even with IM treatment most patients with CML fail to achieve complete molecular 
responses and still have detectable levels of minimal residual disease (MRD), as 
demonstrated by positivity for BCR-ABL transcripts.[2]
Several different mechanisms for IM-resistance have previously been proposed, 
including BCR-ABL gene amplification, clonal evolution and over-expression of Src-
related kinases.[3-8] However, point mutations within the kinase domain of BCR-ABL
account for over 50% of cases of IM-resistance.[9,10] In many instances, with the 
major exception of the T315I mutant, these mutations are only partially resistant to 
IM and either dose escalation [11] or treatment with higher potency new tyrosine 
kinase inhibitors (TKI), such as dasatinib (Sprycel™; BMS-354825; Bristol-Myers 
Squibb, New York, USA) and nilotinib (TasignaTM; AMN107; Novartis, Basel, 
Switzerland) can overcome resistance. [12,13]
There is accumulating evidence to suggest that variable expression of multidrug 
transporters in CML patients’ cells may play a critical role in the clinical response to 
IM treatment. [14] These transporters are transmembrane proteins functioning either 
as efflux or influx pumps for a wide range of compounds. Recent studies on IM influx 
have demonstrated an active uptake mechanism by cells via the organic cation 
transporter OCT-1 (slc22a1), with IM being a substrate for OCT-1.[15] However, the 
interaction of IM with efflux transporters has proven rather controversial. MDR1 (P-
glycoprotein, Pgp; ABCB1), is the archetypal member of the ATP-binding cassette 
(ABC) transporter protein family and has been studied extensively as a factor 
modulating chemotherapeutic drug levels. Recent reports provide biochemical 
evidence that IM may interact with MDR1 as a substrate [16-18] and suggest that 
4MDR1 expression can be a limiting factor in IM distribution in the body.[19] 
Furthermore, several in vitro studies suggest that MDR1 activity confers resistance to 
IM in CML cell lines that have been modified to aberrantly express MDR1. This has 
been demonstrated by modulation of MDR1 function using specific inhibitors that 
abrogate the MDR1-dependent reduction of cell associated IM and restore sensitivity 
to IM.[20-22] Similar results have been obtained from Ph+ IM-resistant cell lines 
using a stable knockdown of MDR1 by RNAi  silencing. [23, 24] Although together
these data suggest that MDR1 mediates resistance to IM, contradictory evidence for 
the role of MDR1 exists. Ferrao et al, demonstrated that MDR1 does not confer IM-
resistance in vitro, as growth of K562 cells engineered to over-express MDR1, in the 
presence of IM, did not differ from control K562 cells.[25] Additionally, studies from 
Zong et al on the in vivo contribution of MDR1 to IM-resistance, performed in a
murine model of CML, showed no difference in haemopoietic response to IM upon
expression of MDR1.[26] However, despite the controversy regarding the role for 
MDR1 in mediating IM-resistance in cells lines and murine models, there has as yet
been no data for primitive  CML cells derived from patients in CP. 
Previously we and others have identified a rare population of primitive (CD34+38-), 
leukaemic, quiescent stem cells (qSC), that comprise <5% of total CD34+ cells and 
can regenerate CML populations in immunodeficient mice.[27-29] In addition, we 
have shown that CD34+ and CD34+38- cells express significantly increased levels 
(>10-fold) of BCR-ABL at the mRNA and protein levels, with respect to mature 
mononuclear cells.[30] Our recent findings demonstrate that primitive CD34+ and 
CD34+38- cells are both insensitive to IM in vitro, even at concentrations [31] that 
exceed the approximate in vivo peak steady state plasma level.[32] We have 
previously shown that ABCG2 over-expression is not associated with IM-resistance in 
primitive CML cells, as at therapeutic concentrations IM was shown to be an inhibitor 
of ABCG2 rather than a substrate.[33] The present study was designed to investigate 
the role of MDR1 in the resistance of CML CD34+ cells to IM and to determine the 
5type of interaction (substrate/inhibitor) IM exhibits with the MDR1 transporter in 
these primitive cells. 
We report here direct measurements of cell associated levels of IM in cell lines, 
CD34+ CML and non-CML cells, using an analytical approach based on high pressure 
liquid chromatography (HPLC). Additionally, in CML patient derived CD34+ cells, 
we investigated the level of expression of the MDR1 gene and whether modulation of 
the function of MDR1 protein would result in increased cell associated levels of IM,
thereby enhancing inhibition of BCR-ABL activity and cellular proliferation, thus 
sensitising the primitive population to IM treatment.
Materials and Methods
Cell lines and primary samples
K562-wild type (K-WT) and the transduced cell line K-MDR-GFP (K-MDR), which 
over-expresses the MDR1 gene, were donated by Dr T. Southgate and the late Dr L.
Fairbairn (Paterson Institute for Cancer Research, Manchester, UK). These were 
cultured in RPMI supplemented with 10% v/v FCS, 1mmol/L glutamine and 1mmol/L 
streptomycin/penicillin. Cells from newly diagnosed patients with CP CML and from 
patients with Ph- haematological disorders that do not involve haemopoietic stem cells
(non-CML) were harvested by leukapheresis and enriched to >95% CD34+ using 
CliniMACS (Miltenyi Biotec, Auburn, CA) according to the manufacturer’s 
instructions and cryopreserved in 10% (v/v) dimethyl sulfoxide in ALBA (4% [w/v] 
Human Albumin Solution, Scottish National Blood Transfusion Service). Further 
selection of CD34+38- cells was achieved by fluorescence activated cell sorting 
(FACS; BD FACSAria). Primary cells were cultured in IMDM with BIT, 1mmol/L 
glutamine, 1mmol/L streptomycin/penicillin, 40ng/mL LDL and 10-4mol/L 2-
mercaptoethanol, with or without 5 growth factors (GF) where indicated, as 
previously described.[31]
6RNA synthesis 
Cells were washed twice in PBS and total RNA was isolated from pellets using the 
RNeasy Mini Kit (Qiagen, Crawley, UK). The resulting RNA was quantitated using a 
Nanodrop spectrophotometer Nd-1000 (Labtech International, East Sussex, UK) and 
the integrity of the RNA was determined using the Agilent 2100 Bioanalyser (Agilent 
Technologies, Wokingham, UK). RNA was synthesised to cDNA by the High 
Capacity cDNA Archive kit (Applied Biosystems, Warrington, UK) and the cDNA 
samples were stored at -80ºC until further use. RNA (1μg aliquots) derived from 
normal CD34+ cells isolated from mobilised peripheral blood (mPB) was purchased 
from StemCell Technologies UK (London, UK).
Semi-quantitative RT-PCR 
The expression of transporter gene MDR1 [31,34-36] was measured using custom 
Taqman Low Density Array (TLDA) cards (Applied Biosystems, Warrington, UK). 
The formula used for the relative quantification of MDR1 was based on the 
comparative crossing threshold method. This is calculated by initially subtracting the 
endogenous control Ct (cycle number at which the curve intersects the threshold) 
from the target gene Ct to give a ΔCt. The comparison between the target CML 
sample with regard to the normal calibrator sample is then calculated by subtracting 
the ΔCt value of the normal sample from the CML sample to give a ΔΔCt, which is 
then used as the number in the power calculation 2-ΔΔCt (i.e. 2-(ΔCt[target sample]-ΔCt[calibrator 
sample]), providing the fold difference in CML compared to the normal sample.
Cell associated IM levels and the effect of efflux transporter inhibition
For a single experiment, cells were plated at 5x104 cells/mL/well for cell lines and 
1x105 cells/mL/well for patient cells and left to equilibrate for 2h at 37ºC and 5% 
CO2, prior to addition of different concentrations of IM for 2h. To test the effect of 
MDR1 inhibition on cell associated levels of IM, cells were incubated with 5M 
PSC833 (a specific inhibitor of MDR1; Dr R. Clark, University of Liverpool, UK) for 
730 mins, prior to addition of IM (5, 10 M) for 2h. PSC833 was maintained in the cell 
culture medium throughout IM incubation.
Following drug treatment, cells were centrifuged at 276g for 10 mins at 4ºC and the 
resulting pellet was washed three times with 1mL ice-cold PBS, collecting the 
supernatant each time for analysis of extracellular IM levels to assure that the number 
of washes was sufficient in eliminating any extracellular IM. For cell associated 
concentrations, cells were lysed with 100L 0.2M NaOH/1% SDS, vortexed and 
sonicated for 2 mins. For extracellular IM levels, 100L of supernatant was used from 
washing steps. An internal standard (IS), clozapine was added at 100g/mL to each 
sample prior to extraction. Extraction of IM from lysed cells and supernatants was 
performed by protein precipitation with 150L of ice-cold acetonitrile, followed by 
brief vigorous mixing and centrifuged at 432g for 15 mins at 4ºC.
The cell associated IM content of drug-treated cells was determined by a modified
HPLC isocratic elution method. Analysis was performed on a Dionex Ultimate 3000 
LC with a UV detector (260nM) and temperature controlled column compartment 
(35ºC). A 150x2mm, 5m Gemini Phenomenex reversed phase column was used at a 
flow rate of 0.450mL/min. The mobile phase, used for LC analysis, consisted of 65:35 
methanol:20mM NH4Ac buffer, pH10. Intracellular IM levels as well as extracellular 
levels were analysed by injecting 20L of extracted lysed cells or 
supernatant/washing solution onto the HPLC column. 
Cell volumes
Cell volumes (Vcell) were calculated based on the equation: Vcell=
4/3  r3. The cell 
radius was measured by taking images of live cells (~30 cells) in suspension with an
Olympus CKX41 microscope and using CellB imaging software.  
Efflux studies
8The MDR1 efflux protocol was a modification of the protocol previously described
for ABCG2 efflux transporter function.[33] Briefly, cells were incubated with either 
PSC833 (5M) and/or IM (1-5M) to block pump activity before the addition of 
rhodamine 123 (0.5g/mL) (MDR1 substrate). Cells were then washed in ice-cold 
medium and analysed by flow cytometry.
Cellular analysis
Measurement of intracellular levels of phosphorylated CrkL (p-CrkL) , assessment of 
apoptotic cells, viability counts and high resolution tracking of cell division by CFSE 
(carboxyfluorescein succinimidyl ester) staining, were performed on CML CD34+
cells, treated either with IM (5M) or PSC833 (5M), alone or in combination,  for 
72h. Intracellular p-CrkL and CFSE staining were performed and analysed by flow 
cytometry as described previously. [28-30, 39] For analysis of apoptosis, cells were 
incubated with 5μl Annexin V-FITC and 10μl Viaprobe in 100μl Annexin binding 
buffer for 15 mins in the dark. Finally, 400μl Annexin buffer were added to the cells
and fluorescence was read by flow cytometry, within the hour, to identify apoptotic
(Annexin V + Viaprobe positive) cells. Viability of CML CD34+ cells was measured 
by trypan blue dye exclusion assay.
Statistical analysis
Results are shown as the mean ± standard deviation (SD) values obtained in repeated
independent experiments. Differences between treatments were assessed using the 
paired Student’s t-test.
Results 
Efficiency of HPLC methodology for the measurement of cell associated IM levels
The lower limit of quantification (LLOQ) of this assay was assigned as 0.1M 
(58.97ng/mL) IM, with signal to noise ratio >5. The analytical method was validated 
for accuracy and precision, based on 5 different concentrations, using quality controls 
(QCs) at 0.5 (294.8ng/mL), 1 (589.7ng/mL), 5 (2948ng/mL), 10 (5897ng/mL) and 
950M (29480ng/mL), for cell lysates performed in 5 replicates per day, over a 3 day 
period. Cell lysates were derived from K-WT cells. For all the QCs performed with
cell lysates, accuracy was within 11% of the nominal value, while precision ranged 
from 3.8-7.5% as measured by the coefficient of variance. Recovery of IM by 
acetonitrile precipitation was determined at 2 concentrations (1 and 10M) and gave 
92% recovery of IM from cell lysates. Results were expressed as pg/cell, taking into 
account the number of cells per experiment, the volume of lysis buffer and extraction 
solvent and the injection volume.  
Uptake of IM in cell lines and in CML and non-CML CD34+ cells
HPLC analysis was used to determine the cell associated levels of IM achieved in 
vitro at concentrations of IM approximating the steady state plasma level in patients 
taking 400mg per day (1 and 5M) [32] and at a higher concentration of 10M. 
Although incubation of the Ph- cell line HL60 with 1M IM lead to similar cell 
associated IM levels as for the Ph+ cell line K-WT (HL60: 1.60±0.69pg/cell, n=3; K-
WT: 1.83±0.75pg/cell, n=7; p=0.77), incubation with 5 (p=0.02) or 10M (p=0.05) 
IM revealed significantly lower levels of IM in HL60 versus K-WT (Figure 1a).
Lower levels of drug uptake were observed in CP CML CD34+ cells (5M: 
1.36±0.36pg/cell, n=6; 10M: 2.39±0.36pg/cell, n=6) and non-CML CD34+ samples
(5M: 0.79±0.25pg/cell, n=3; 10M: 1.77±0.24pg/cell, n=6) (Figure 1b). Analysis of 
IM accumulation in the CD34+38- subset of CML samples, which approximates the 
qSC population in vivo, revealed a lower accumulation at both concentrations (5M: 
0.47 ± 0.09pg/cell, n=6; 10M: 0.97 ± 0.09pg/cell, n=6) compared to the total CML 
CD34+ population (p=0.04 and 0.009) (Figure 1b). However, measurement of the cell 
volumes demonstrated that there were significant cell volume differences between cell 
lines (HL60: 1498m3; K-WT: 2635m3) and patient cells (CML CD34+: 800m3; 
CML CD34+38-: 641.1m3; non-CML CD34+: 588.7 m3), which may explain the 
higher cell associated levels observed in cell lines (Table 1).
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MDR1 efflux transporter expression and functionality in CML CD34+ cells 
To determine whether MDR1 activity contributed to cell associated levels of IM, we 
investigated MDR1 expression in CML and normal CD34+ cells and determined
whether the MDR1 transporter was functional in these cells.
MDR1 mRNA expression was measured in 7 CP CML and 11 normal CD34+ samples 
using real time qPCR. Using GAPDH as the endogenous control, CML samples 
consistently expressed MDR1 mRNA at approximately 7-fold less than their normal 
counterparts (CML: ΔCt=8.33±0.47, normal: ΔCt=5.44±0.24 (p=0.0003)). The 
protein function of MDR1 was measured by substrate displacement studies using the 
specific MDR1 fluorescent substrate rhodamine 123 and the specific MDR1 inhibitor 
PSC833. The assay was initially validated in K-WT and K-MDR cells (Figures 2a & 
b). K-MDR efficiently effluxed 50ng/mL of rhodamine 123 and this efflux was
maximally inhibited by 5μM PSC833 (Figure 2b), confirming that MDR1 was 
functional in the cell line K-MDR. In CML samples (n=3), minimal efflux was 
observed in the absence of PSC833 compared to the presence of this specific inhibitor 
(Figure 2c), suggesting very low levels of functional MDR1 protein, in keeping with 
the mRNA data. Although there was a slight increase in rhodamine 123 retention in 
the presence of PSC833, the difference observed did not reach statistical significance.
Effect of IM on MDR1 efflux transporter function in CML CD34+ cells
To determine whether IM interacts with the MDR1 efflux transporter, the substrate 
displacement assay was repeated by replacing the known inhibitor PSC833 with IM. 
In K-MDR cells, the addition of IM resulted in a concentration-dependent decrease in 
the efflux of rhodamine 123, although even 5M IM did not fully reverse rhodamine 
123 efflux as shown for PSC833 (Figure 3a). When this assay was repeated in primary 
CML CD34+ cells, no increase in rhodamine 123 fluorescence was observed (Figure 
3b).
Effect of inhibition of MDR1 on IM uptake by CML CD34+ cells 
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To further confirm the results of the displacement assays, cell associated levels of IM 
were measured by HPLC for cells cultured in the presence and absence of PSC833. 
There were no significant differences in the concentration of IM, in the presence or 
absence of PSC833, for K-WT, CML or non-CML CD34+ cells (Figures 4a-c), 
supporting the earlier observation that MDR1 is expressed at too low a level to be of 
functional significance in these cells (CML CD34+ cells 5M IM: 1.13±0.41pg/cell,
vs 5M IM + 5M PSC833: 0.59±0.26pg/cell, n=4, p=0.17).
Effect of inhibition of MDR1 on primitive CML CD34+ cell proliferation and viability 
To confirm that MDR1 activity does not limit the action of IM, the effect of MDR1 
inhibition on the proliferation of CML CD34+ cells was evaluated. Cells were cultured
with 5GF, in the presence or absence of either 5M PSC833, 5M IM or both, for 
72h. Incubation with PSC833 resulted in a significant reduction in total viable CML 
CD34+ cells, as compared to untreated control, similar to that observed with IM 
treatment (untreated, 177±21.9x104 cells vs PSC833 treated, 80±12x104 cells, 
p=0.002; or vs IM treated 90.03±10.74x104 cells, p=0.002; all n=4), suggesting that 
PSC833 exerts an inhibitory effect on CML CD34+ cells. In addition, the combination 
of PSC833 and IM further decreased the total number of viable CD34+ cells compared 
to IM alone (PSC833 5M + IM 5M, 30.2±7.1x104 cells, n=4, p=0.002 compared to 
untreated), although this was not significant when compared to either IM or PSC833 
alone (Figure 5a). The effect of PSC833 on the undivided CD34+ population 
remaining following 72h of culture, as defined by CFSEmax, was also examined 
(Figure 5b). As demonstrated previously, IM resulted in an accumulation of undivided 
CD34+ cells through its anti-proliferative effect,[31] however, PSC833 alone or in 
combination with IM had no effect on this critical qSC population.
Effect of inhibition of MDR1 on CrkL phosphorylation and apoptosis in CML CD34+ 
cells
The previous results suggested that the combination of IM and PSC833 had an 
additive effect when total cell numbers were used as a measure of drug action. In 
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addition, further analysis demonstrated a slight increase in apoptosis with either IM or 
PSC833 alone, or in combination (Figure 5d). However, this combined effect may be 
due to either MDR1 inhibition or non-specific toxicity. To further define this
inhibition, we analysed the effect on BCR-ABL activity by measuring the 
phosphorylation of the downstream substrate CrkL, which is used as a surrogate
marker for establishing the level of BCR-ABL activity. As expected, following 72h 
treatment, IM-treated CML CD34+ cells showed reduced p-CrkL activity, however 
PSC833 alone had no effect. Furthermore, the combination of PSC833 and IM did not 
further reduce p-CrkL levels in comparison to IM alone (Figure 5c). Therefore, 
PSC833 did not potentiate the inhibition of BCR-ABL by IM strongly suggesting that 
the decreased cell numbers seen with PSC833 or PSC833 with IM occurred through a 
BCR-ABL independent mechanism. 
Discussion
With the introduction of TKIs such as IM, the majority of CML patients now expect 
to achieve cytogenetic and even molecular responses.[1] However, few patients 
achieve sustained molecular remission and a significant proportion develop IM-
resistance. Although BCR-ABL domain mutations are a recognisable cause of IM-
resistance, other contributory factors have been suggested including the expression of
proteins that facilitate the transport of IM in and out of cells. In particular, many 
studies have suggested that MDR1 and ABCG2 play an important role in IM-
resistance. We have previously demonstrated that although ABCG2 is over-expressed 
in CML CD34+ in comparison to normal CD34+ cells, IM acts as an inhibitor for this 
transporter and thus the increased expression of ABCG2 does not affect cell 
associated IM levels nor mediate resistance in this population.[33] 
In this study we extended our work on efflux transportation of IM by focusing on the 
significance of MDR1 in modulating the cellular accumulation of IM in CD34+ CP 
CML cells, a cell population that includes persistent qSCs that we have proposed to be 
responsible for the persistence of disease after treatment. Here, we have shown that 
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transcript levels for MDR1 are in fact lower in CML CD34+ cells in comparison to the
normal CD34+ population. Jiang et al have also compared the expression of MDR1 in 
leukaemic and normal CD34+ cells and reported an elevated expression of MDR1 in 
the leukaemic population.[40] Although we do not fully understand this disparity in 
results it may relate to factors that would render valid comparison of these two studies 
impossible. Jiang et al examined only specimens in which long-term culture initiating 
cells (LTC-ICs) were predominately Ph+/BCR-ABL+ (only 10-15% of new diagnosis 
CML in CP). This may have led to preferential selection of more advanced phase 
CML samples in which MDR1 expression might be expected to be elevated. In 
contrast, the cohort analysed in this work was unselected in terms of LTC-IC 
genotype. We therefore consider that our data will better reflect the baseline 
expression in standard CML CP CD34+ cells. Furthermore, Thomas et al also 
measured expression of MDR1 in patient samples and found that although MDR1
gene transcripts were detectable in peripheral blood leukocytes from patients in both 
CP and accelerated phase, they were expressed at low levels, which is in concordance 
with our finding that primary CD34+ CML cells express low levels of MDR1 mRNA
and demonstrate only weak MDR1 function.[41] These results are supported by
previous studies that measured MDR1 functional activity in mononuclear cells 
(MNC) from peripheral blood of patients in CP or accelerated phase CML and 
similarly found no significant MDR1 activity.[42,43]
We also found that treatment of CML CD34+ cells with IM, in combination with 
PSC833, does not enhance cell associated IM levels, indicating that MDR1 does not 
mediate energy-dependent exclusion of IM from these cells. Furthermore, in the cell 
line engineered to over-express MDR1, K-MDR, we observed a concentration-
dependent increase in the accumulation of the known MDR1 substrate rhodamine 123 
by IM, demonstrating that IM interacts with MDR1 as an inhibitor rather than 
substrate. Our data is consistent with the data of White et al, suggesting that IM is not 
effluxed by MDR1, but instead may actually inhibit MDR1-mediated efflux of known 
substrates.[44] Furthermore, inhibition of MDR1 with PSC833, in combination with 
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IM, did not enhance the efficacy of IM alone against bulk CD34+ cells or the qSC 
fraction, as assessed by viable cell number (qSC), apoptosis and BCR-ABL inhibition. 
Previously, it has been speculated by Shukla et al that there may be a narrow 
concentration range in which ABC transporters can transport IM. [17] This was 
derived from the contradictory results on the interaction of IM with ABCG2. Firstly, 
Houghton et al [45] reported that 1M 14C-IM accumulation was similar in cell lines 
expressing functional and non-functional ABCG2. However, Burger et al [46] found 
that at 10 fold lower concentrations intracellular levels of 14C-IM were significantly 
reduced in cell lines that over-expressed ABCG2. Although the behaviour of IM in 
relation to its interaction with transporter proteins might change in low and high 
concentrations, in our study we have used concentrations that relate to the steady state 
trough plasma levels (<5M) previously reported in patient clinical trials. [32, 47]    
Finally, we have previously reported that the inhibitory concentrations (IC50) for IM, 
in proliferation and cell viability assays, is significantly lower for K-WT than for 
primary CD34+ CML cells (0.6, and 5M respectively).[31] It was therefore 
interesting to observe a differential accumulation of IM, which may in part explain the 
variation in sensitivity to IM treatment between cell lines and primary CD34+ cells.
However, cell associated IM levels may be simply related to cell volume. By direct 
measurements of the cell diameter, we were able to calculate cell volumes and found 
that there were differences in cell volume between cell lines and patient cells, which 
may explain the higher cell associated levels observed in the larger cell lines. 
However, if a direct relationship between cell volume and IM accumulation is 
assumed, the amount we measured in the CML CD34+38- cell population is lower 
than that expected when compared to total CML CD34+ cells (Table 1). This may 
imply that cell volume is only one parameter influencing cell associated IM levels and 
as we have shown that efflux transportation is not a strong determinant of IM level, 
influx may play a critical role. OCT1has been shown to be important for IM uptake, 
and Jiang et al [40] have previously reported that CML stem cells (CD34+38-) have 
particularly low expression of this influx transporter. Similarly, we have found that 
15
OCT-1 mRNA is undetectable in CD34+ CML cells (unpublished data).  Thus, the 
lack of OCT-1 may be in part responsible for the low cell associated IM levels in 
primitive CML that we report here. In general, OCT-1 influx transport is proving to 
be an important clinical determinant to IM-response in patients. [14,15,48] White et al
showed that patients with high OCT-1 activity achieved significantly greater 
molecular responses over 24 months of IM treatment than patients with low OCT-1 
activity [14]. Thus, it seems that in general in CML cells influx rather than efflux is a 
strong determinant of cell associated IM levels and response to treatment,  however 
the very low or undetectable levels of OCT-1 in the most primitive cells implies that 
there maybe another as yet unidentified mechanism involved.
Taken together, our results demonstrate conclusively that MDR1, although present at 
low levels in primary CD34+ CML cells, is unlikely to mediate IM-resistance in this 
primitive population. Even when expressed at higher levels, such as in advanced 
phase CML, MDR1 is unlikely to mediate IM-resistance since IM appears to inhibit 
MDR1, rather than interact with the transporter as a substrate. Whether alternative 
members of the ABC drug efflux transporter family [49] are expressed on CD34+
CML cells and capable of mediating IM-resistance in this cellular context is as yet 
unknown.
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Titles and Legends to Figures:
Figure 1: Cell associated levels of IM. (a) Levels of IM in K-WT (n=7) and HL60 
(n=3) cell lines. (b) Levels of IM in CML (n=6) and non-CML (n=3) CD34+ cells and 
the CML CD34+38- subpopulation (n=6). Cell associated levels were measured in 
5x104 cells for cell lines and 1x105 cells for primary cells as described in Materials & 
Methods. Statistical analysis was performed between groups treated with the same 
concentration of IM, p values are reported in graphs only when statistically significant 
(p<0.05).
Figure 2:  The function of MDR1 in Ph+ cell lines and CML CD34+ cells. The effect 
of the specific MDR1 inhibitor PSC833 to inhibit substrate rhodamine 123 efflux was 
determined in (a) K-WT, (b) K-MDR cells and (c) primary CML CD34+ cells. MDR1 
function was measured by substrate displacement assays using flow cytometry 
analysis as described in Materials & Methods. Unstained cells (black fill), cells 
treated with rhodamine 123 in the absence (light grey fill) and presence of PSC833 
(dark grey fill). The plots are representative of 3 independent experiments.
Figure 3: IM interaction with MDR1 protein. Increasing concentrations of IM were 
added prior to addition of the specific MDR1 substrate rhodamine 123 and compared 
with the effect of the known inhibitor, PSC833 in (a) K-MDR cells and (b) primary 
CML CD34+ cells. MDR1 function was measured by substrate displacement assays 
by flow cytometry as described in Materials & Methods. Representation of different 
treatments is assigned on FACS plots. The plots are representative of 3 independent 
experiments.
Figure 4: Effect of the MDR1 specific inhibitor PSC833 on the cell associated levels 
of IM. Levels of IM in K-WT cell line (n=3) (a), CML (n=4) (b) and non-CML 
CD34+ (n=3) cells (c). Cell associated levels of IM (5 and 10M) were measured in 
the presence or absence of 5M PSC833 in 5x104cells for K-WT and 1x105 cells for 
primary cells by HPLC as described in Materials & Methods. No statistical 
significance was observed in cell associated levels of IM in cells treated with the same 
amount of IM in the presence or absence of PSC833 (p>0.05).
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Figure 5: The effect of inhibition of MDR1 function with PSC833 on efficacy of IM 
in CML CD34+ cells. Effect of PSC833 on (a) the viability of total CD34+ cells, (b) 
the undivided CML CD34+ population, (c) p-CrkL  and (d) CD34+ cells that undergo 
apoptosis. CD34+ cells were seeded at 1x105 cells/mL and treated with either IM or 
PSC833 alone or in combination for 72h and measured as described in Materials and 
Methods. Results are expressed as the mean ± SD for three independent experiments; 
*P<0.05, **P<0.01 significantly different from no-drug control (ND). 
Table 1: Predictions and comparison of calculated cell associated IM levels based on 
cell size and measured IM levels by HPLC. Predicted IM levels were based on values 
normalised against non-CML CD34+ cell size for primary cells and HL60 for cell 
lines. 
Table 1:
Cell type Actual 
volume
(m3)
Relative 
volume 
(m3)
Assumed IM cell 
associated  
concentrations 
measured (pg/cell)
IM cell 
associated 
concentrations 
(pg/cell ± SD)
Non-CML CD34+ 589 1.00 0.79 0.79±0.25
CML CD34+38- 641 1.09 0.86 0.47±0.09
CML CD34+ 800 1.36 1.07 1.36±0.36
HL60 1498 1.00 3.51 3.51±0.97
K562 2635 1.76 6.18 9.01±2.74
p=0.02
p=0.05
p=0.009
p=0.04
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Inhibition of MDR1 does not sensitise primitive chronic myeloid leukaemia CD34+ cells to imatinib.  
S Hatziieremia et al
I am pleased to submit this article for consideration for publication in Experimental Hematology.  In 
this work, we confirm that efflux by MDR1 is not a mechanism for resistance of CML stem cells to 
imatinib.  We uniquely combine HPLC quantification of cell associated drug concentrations with flow 
cytometry based functional assays for transporter activity in the primitive (CD34+ CD38- ) 
subpopulation of CML stem / progenitor cells.
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